Pfizer announced results from its Phase 3 study of Lyrica (pregabalin) for the treatment of restless leg syndrome (RLS).
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.